PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28846831-12	2017	Both PCCs reversed apixaban"s effect on ETP; the differences in adjusted mean change from pre-PCC baseline to end of infusion were 425 nm min (95% confidence interval [CI] 219.8-630.7 nm min; P < 0.001) for Cofact, and 91 nm min (95% CI - 31.3 to 212.4 nm min; P > 0.05) for Beriplex.	apixaban	19-27	crystallin gamma D	Homo sapiens	5-8	
25630710-8	2015	CONCLUSION: aPCC was more effective than PCC or rFVIIa in reversing in vitro the effects of apixaban.	apixaban	92-100	crystallin gamma D	Homo sapiens	13-16	
34837144-0	2021	Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.	apixaban	39-47	crystallin gamma D	Homo sapiens	23-26	
33609094-3	2021	RESULTS: 4F-PCC was ordered for 427 patients with warfarin-, apixaban-, or rivaroxaban-associated hemorrhage.	apixaban	61-69	crystallin gamma D	Homo sapiens	12-15	
25136597-10	2014	Based on human clinical trial evidence, the 4-factor PCC (Kcentra) is suggested for patients with refractory rivaroxaban- or apixaban-associated hemorrhage.	apixaban	125-133	crystallin gamma D	Homo sapiens	53-56